Your session is about to expire
← Back to Search
PET Imaging for Neuroendocrine Cancer
Study Summary
This trial will help determine if a correlation exists between how a tumor looks on a DT PET scan and how aggressive it is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 2 trial • 59 Patients • NCT01146054Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is a mix of neuroendocrine and non-neuroendocrine types.My cancer is not a lung neuroendocrine tumor or related to non-digestive system cancers.My tumor is growing or dividing quickly.I have a confirmed neuroendocrine tumor in my digestive system.I have not been treated or have been treated for advanced cancer.You are allergic to FDG (a type of imaging agent).My cancer is a type of aggressive neuroendocrine tumor.My tumor is classified as Grade 2-3, indicating a moderate to high level of abnormality.My tumor is a Grade 1 neuroendocrine tumor.I am 18 years old or older.I have had or am scheduled for a 68Ga-DOTATATE PET/CT scan.
- Group 1: 18F-FDG PETCT scan
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an opportunity for individuals to join the experiment?
"Based on the information provided by clinicaltrials.gov, this study is still enrolling patients as of May 20th 2022. The trial was initially launched in March 4th 2021."
What other investigations have been conducted surrounding this therapy?
"Currently, 18 studies are being conducted in relation to this treatment. One is at the pivotal Phase 3 stage and 19 different sites across Wuhan, Hubei province are running tests on it."
What conditions can this particular remedy ameliorate?
"This pharmaceutical is typically used to manage seizures, but it has also been demonstrated as a viable option for treating coronary artery disease (CAD), cancer, and positron emission tomography."
What is the current enrollment of this clinical research endeavor?
"Affirmative. According to clinicaltrials.gov, this research is actively enrolling participants; it was first published on March 4th 2021 and the most recent update occurred on May 20th 2022. The study requires 40 individuals from one medical site."
Share this study with friends
Copy Link
Messenger